Rapamycin regulates autophagy and cell adhesion in induced pluripotent stem cells
- 1.9k Downloads
Cellular reprogramming is a stressful process, which requires cells to engulf somatic features and produce and maintain stemness machineries. Autophagy is a process to degrade unwanted proteins and is required for the derivation of induced pluripotent stem cells (iPSCs). However, the role of autophagy during iPSC maintenance remains undefined.
Human iPSCs were investigated by microscopy, immunofluorescence, and immunoblotting to detect autophagy machinery. Cells were treated with rapamycin to activate autophagy and with bafilomycin to block autophagy during iPSC maintenance. High concentrations of rapamycin treatment unexpectedly resulted in spontaneous formation of round floating spheres of uniform size, which were analyzed for differentiation into three germ layers. Mass spectrometry was deployed to reveal altered protein expression and pathways associated with rapamycin treatment.
We demonstrate that human iPSCs express high basal levels of autophagy, including key components of APMKα, ULK1/2, BECLIN-1, ATG13, ATG101, ATG12, ATG3, ATG5, and LC3B. Block of autophagy by bafilomycin induces iPSC death and rapamycin attenuates the bafilomycin effect. Rapamycin treatment upregulates autophagy in iPSCs in a dose/time-dependent manner. High concentration of rapamycin reduces NANOG expression and induces spontaneous formation of round and uniformly sized embryoid bodies (EBs) with accelerated differentiation into three germ layers. Mass spectrometry analysis identifies actin cytoskeleton and adherens junctions as the major targets of rapamycin in mediating iPSC detachment and differentiation.
High levels of basal autophagy activity are present during iPSC derivation and maintenance. Rapamycin alters expression of actin cytoskeleton and adherens junctions, induces uniform EB formation, and accelerates differentiation. IPSCs are sensitive to enzyme dissociation and require a lengthy differentiation time. The shape and size of EBs also play a role in the heterogeneity of end cell products. This research therefore highlights the potential of rapamycin in producing uniform EBs and in shortening iPSC differentiation duration.
KeywordsActin cytoskeleton Adherens junctions Autophagy Differentiation Embryoid body Induced pluripotent stem cells Rapamycin
Analysis of variance
α-Smooth muscle actin
Induced pluripotent stem cell
Microtubule-associated proteins 1A/1B light chain 3-I
Mouse embryonic fibroblasts
Mammalian target of the Rapamycin
Standard error of means
Transmission electron microscopy
Induced pluripotent stem cell (iPSC) technology enables conversion of patients’ somatic cells into embryonic stem (ES)-like cells  which can be differentiated into the major cell types in the body, raising the expectation of personalized medicine to treat patients with their own somatic tissue-derived cells. This technology also offers an opportunity to generate human cell models of diseases for therapeutic development, which has not kept pace with pharmaceutical investment in recent decades. A major impediment to drug discovery is attributable to the lack of suitable disease models of human origin, because species differences may totally affect drug efficacy . Some disease pathologies are shown to be recapitulated in the culture dish. For example, many patient-specific iPSCs have been generated to investigate disease progression in vitro and disease-related phenotypes are partially preserved in iPSC-derived cells [3, 4, 5, 6]. Recent successes in the growth of “mini-organs”—that is, 3D retina [7, 8] and cerebral organoids —may provide 3D human disease models. However, there are challenges in phenotyping iPSCs prior to the development of screening assays, which include lengthy differentiation durations and heterogeneity of the end cell products.
The differentiation, survival, and self-renewal of human stem cells can be regulated by a 3D microenvironment including shape and size [7, 8, 9, 10]. Human iPSCs are hypersensitive to cell dissociation reagents, and seconds of exposure to Trypsin/EDTA may lead to failure of iPSC adhesion or survival. Consequently, many laboratories adopt a “cut-and-paste” method to mechanically passage iPSCs, which results in embryoid bodies (EBs) of uncontrollable sizes with irregular shapes, which may potentially contribute to the heterogeneity. The differentiation of mature cell types from human iPSCs is also time consuming. For example, 3–5 months are required to generate functional neurons, astrocytes, or oligodendrocytes [11, 12, 13]. Therefore, accelerated differentiation remains to be optimized.
Efforts have been made to improve the reprogramming efficiency, and autophagy, a process to degrade unwanted proteins, is found to be one of the regulators during cellular reprogramming [14, 15]. Autophagy is conserved from yeast to mammals, and is generally induced by intracellular and extracellular stress. Upon induction, the preautophagosomal structure is formed and elongated to form a phagophore, which engulfs cytoplasmic components, leading to the formation of autophagosomes with double membranes. The genes involved in the autophagy are termed autophagy-related genes (ATGs), and >12 ATGs have been identified. They regulate autophagosome formation through two evolutionarily conserved ubiquitin-like conjugation systems, the ATG12–ATG5 and the ATG8 (LC3)–PE (phosphatidylethanolamine) systems . Microtubule-associated proteins 1A/1B light chain 3-I (LC3B-I) is conjugated with PE to become LC3B-II, which associates with both the outer and inner membranes of the autophagosome. After fusion with the lysosome, the autolysosome is degraded . In mice, Atg3, Atg5, and Atg7 are essential for reprogramming of mouse embryonic fibroblasts [14, 15]. Cells lacking Atg3, Atg5, or Atg7 abrogate iPSC colony formation .
The autophagy pathway can be activated by AMPK signaling, but is normally inhibited by the mammalian target of rapamycin (mTOR) pathway. The presence of hyperactivated mTOR activity in Tsc2 –/– somatic cells completely blocked reprogramming . Consistent with this, rapamycin (an inhibitor of the mTOR pathway at 0.3–1 nM) could increase reprogramming efficiency by 2–3-fold . In addition, 0.1 nM of PP242, a selective inhibitor of mTORC1/mTORC2 binding at the ATP domain, also increased reprogramming efficiency by 5-fold . Other compounds associated with autophagy such as PQ401 (an IGF1 receptor inhibitor) and LY294002 (an inhibitor of PI3K) also increased reprogramming by 4-fold . Mechanistically, mTOR is regulated by SOX2, one of the four reprogramming factors. SOX2 can physically bind to the mTOR promoter and repress mTOR expression, thereby activating autophagy . An appropriate level of autophagy is therefore required for cell reprogramming. However, roles of autophagy in iPSC maintenance and differentiation remain elusive.
In this study, we showed the presence of high levels of basal autophagy activity during iPSC reprogramming and maintenance. Rapamycin alters expression of adherens junctions and actin cytoskeleton, induces iPSC detachment, and results in uniform EB formation. Rapamycin treatment also accelerates differentiation of human iPSCs into three germ layers.
On day 0, human fibroblasts were seeded at a density of 2.0 × 104 cells/well on a six-well dish. Next day, cells were transduced with a polycistronic (OKSM) lentivirus containing four reprogramming factors (SCR544-Human STEMCCA constitutive lentivirus reprogramming kit, SCR544; Millipore) in 700 μl of fibroblast medium, supplemented with 4 μg/ml polybrene (TR-1003; Millipore). On day 2, cells were repeatedly transduced with lentivirus. The medium was then replaced daily with complete fibroblast medium supplemented with 0.25 mM sodium butyrate (NaB, 156-54-7; Sigma) for 4 days. On day 6, six-well dishes were preseeded with γ-irradiated MEF (07GSC6001G, VH Bio Limited) at a density of 1.5 × 105 cells/well. On day 7, transduced cells were trypsinized with 0.25 % Trypsin/EDTA, replated onto preseeded MEF dishes at a density of 3.0 × 104 cells/well, and cultured in KO iPSC medium supplemented with 10 ng/ml bFGF (100-18B; Peprotech) plus 0.25 mM NaB. The medium was changed every other day. The addition of NaB was discontinued after day 20.
Individual iPSC colonies began to emerge after day 14 and were picked up on day 28, mechanically dissociated into smaller pieces by pipetting, and plated into γ-MEF-coated 12-well plates. Selected clones were characterized using alkaline phosphatase activity, RT-PCR, and immunoblotting to detect endogenous expression of OCT4, SOX2, and NANOG, and immunocytochemistry to detect surface markers of SSEA4, TRA 1-60, and TRA 1-81 in addition to the transcription factors (StemLight™ pluripotency antibody kit, 9656; Cell Signaling Technology).
Human iPSC lines were maintained on a feeder-free culture system. The six-well plates were precoated with Geltrex, LDEV-free hESC-qualified reduced growth factor basement membrane matrix (A1413302; Invitrogen). Geltrex was thawed overnight at 4 °C and diluted 1:100 in KO-DMEM medium (10829018; Invitrogen). Each well was coated with 1.5 ml Geltrex and incubated for 1 hour at 37 °C, which was then replaced with the mTeSR1 medium (05850; StemCell Technologies) with 10 ng/ml bFGF at 37 °C and 5 % CO2. iPSCs were cut and pasted into Geltrex-coated wells. The medium was renewed daily and passaged every 6 days. Chemicals such as rapamycin were then added to respective experiments.
For induction of autophagy signaling, iPSC colonies were cultured in mTeSR1 medium supplemented with 0–300 nM rapamycin (R8781; Sigma) for 1–9 days. For autophagic flux assay, human iPSCs were treated with 200 nM rapamycin in the absence or presence of 50 nM bafilomycin A1 for 24 hours (B1793; Sigma) as specified. Cells were collected and protein was subsequently analyzed by immunoblotting.
EB formation by cut-and-paste method
The cut-and-paste method was deployed to make conventional EBs as iPSCs. Spontaneously differentiated cells were removed under a stereomicroscope inside the culture safety cabinet, and fresh medium was added to the remaining iPSC colonies, which were cut into small pieces with a 10 μl pipette tip. The iPSC sections were then scraped off the dish and transferred to a T25 flask in 15 ml EB medium (KO DMEM, KO serum, 1× l-glut, and 1× NNEA plus 50 μl β-mercaptoethanol). The medium was changed every other day, and the EBs were cultured for 7–10 days before plating out for spontaneous differentiation assays.
Antibodies and reagents
The reagents for transmission electron microscopy (TEM) include sodium cacodylate (C0250; Sigma), low viscosity resin kit (AGR1078A; Agar Scientific), 2 % osmium tetroxide (AGR1016; Agar Scientific), 25 % glutaraldehyde solution (23114.02; AMSBIO), and thermanox plastic coverslips (NUNC). For immunocytochemistry, the following antibodies were used: anti-LAMP1 (25630), anti-Syntaxin-6 (12370), and anti-NESTIN (105389) from Abcam; SelectFX® Alexa Fluor® 488 Endoplasmic Reticulum labeling kit (S34200) from Life Technologies; and anti-LC3B from autophagy antibody sampler kit (4445), Alexa Fluor® 488 Goat Anti-Rabbit IgG fluorescent dye (4412), and Alexa Fluor® 555 Goat Anti-Mouse IgG fluorescent dye (4409) from Cell Signaling Technology. For immunoblot experiments, reagents included: anti-α-fetoprotein (A8452), anti-α-smooth muscle actin (A2547), anti-ATG13 (SAB3500502), and ATG101 (SAB3500503) from Sigma; anti-βIII tubulin (G7121) from Promega Corporation; anti-ULK2 (56736) from Abcam; and anti-LC3B, anti-BECLIN-1, anti-ATG5 (D1G9; #8540P, 1:1000), anti-ATG12 and anti-ATG3 autophagy antibody sampler kit (4445), anti-p-ULK1 (Ser317, 6887), anti p-p70S6K (Thr389, 9205), anti-β-Actin (4967), HRP-conjugated anti-mouse IgG antibody (7076), and HRP-conjugated anti-rabbit-IgG antibody (7074) from Cell Signaling Technology. MitoGreen (a green-fluorescent mitochondrial dye) was purchased from Promokine (PK-CA707-70054).
Transmission electron microscopy
iPSCs were cultured on Thermanox coverslips in six-well plates coated with Geltrex, rinsed with prewarmed (37 °C) 0.1 M cacodylate buffer, fixed with 2 % glutaraldehyde and 2 % paraformaldehyde in 0.1 M cacodylate buffer for 3 hours at room temperature, rinsed again with cacodylate buffer, and post fixed with 1 % osmium tetroxide in cacodylate for 1 hour at room temperature. Samples were then rinsed with cacodylate buffer, dehydrated through a series of graded ethanol, embedded in low-viscosity resin according to the standard protocol, and polymerized at 60 °C for 48 hours. Ultra-thin sections were obtained using a diamond knife, on a Leica Reichert Jung ultra-microtome, and stained with the contrasting agents, uranyl acetate and lead citrate, in a Leica EM AC20 stainer. Sections were examined with a Hitachi H7000 transmission electron microscope fitted with a 1 K Hamamatsu digital camera, and images were captured using AMTV542 Image Capture Engine software.
To investigate the effect of rapamycin, iPSC colonies or the EB-like spheres were transferred to a μ-Slide eight-well glass bottom flask (80826; ibidi GmBH) coated with Geltrex. Cells were fixed with 4 % paraformaldehyde for 10 min at room temperature and washed with PBS three times before permeabilization using 0.5 % Triton X-100 for 10 min. Nonspecific binding was blocked with 5 % normal goat serum in PBS containing 0.5 % Trion X for 1 hour prior to incubation with primary antibodies overnight at 4 °C. The wells were washed three times with PBS and incubated with secondary antibodies for 1 hour at room temperature. The nuclei were visualized by Hoechst counterstaining for 10 min. After washing with PBS, the immunofluorescence was visualized with the Andor Revolution spinning disk confocal microscope, using Andor IQ2 software. The samples were imaged using a combination of λ405 nm, λ488 nm and λ564 nm lasers.
Following experimental treatments, cell pellets were resuspended in NP40 cell lysis buffer (FNN0021; Invitrogen) supplemented with protease inhibitor cocktail (P2714; Sigma). Lysate was then centrifuged at 13,000 rpm for 10 min at 4 °C, and the supernatant was collected and used for immunoblotting. The protein concentration was determined and the samples were denatured in sample buffer (62.5 mM Tris–HCl pH 6.8, 2 % SDS, 10 % glycerol, 2 % mercaptoethanol, and 0.01 % bromophenol blue) at 95 °C for 5 min. Proteins were resolved on 10–15 % SDS-PAGE gels and then electrophoretically transferred to a polyvinylidene difluoride (PVDF) membrane (162-0177; Bio-Rad). The transfer efficiency was checked by Ponceau-S red staining (P7170; Sigma). The membranes were washed with Tris-buffered saline containing 0.1 % Tween-20 (TBST) for 5 min, incubated in blocking buffer for 1 hour at room temperature, and incubated overnight at 4 °C with primary antibodies. They were then washed three times for 5 min each with TBST, incubated with secondary antibodies for 1 hour at room temperature, and washed in TBST. Finally, the membranes were visualized by enhanced chemiluminescence using ECL™ Prime (GZ28980926; Amersham Biosciences). The immunoblot band densities were normalized with the unphosphorylated protein, actin, or GAPDH, and quantified using a densitometer in the Scion image analysis program (National Institutes of Health, Bethesda, MD, USA).
Data analysis and statistical methods
Data were expressed as the mean ± standard error of means (SEM) or mean ± SD as indicated. Significance was assessed using one-way analysis of variance (ANOVA) followed by the Tukey–Kramer test using GraphPad Prism version 5. p < 0.05 was considered significant, and p < 0.01 very significant.
Mass spectrometry analysis
The iPSCs were lysed in 1 % SDS and the lysates were processed using the FASP protocol as published previously . Briefly, the cell lysates were sonicated, detergents were removed by sequential washes in spin columns, and proteins were digested with trypsin. The peptides were analyzed on a Q-Exactive Mass Spectrometer as described previously . The proteins were identified and quantified with the MaxQuant 1.5 software suite by searching against the human uniprot database, with N-terminal actylation and methionine oxidation as variable modification and a FDR of 0.01. Mass accuracy was set a 4.5 ppm for the MS and 20 ppm for the MS/MS. LFQ was performed by MaxLFQ as described previously . One-way ANOVA was carried out to compare rapamycin-treated samples with control iPSCs. The mean expression levels (M) and SEM were quantified, and folds of changes in the treated samples were calculated against the control iPSCs (set as 1). p < 0.05 was considered statistically significant. A total of 220 proteins which were significantly altered after rapamycin treatment were analyzed by the STRING program for pathway using GO biological processes and GO cellular components.
Autophagy is a prominent feature of reprogramming cells and stable iPSCs
Double immunofluorescence staining was carried out with anti-LC3B (an autophagy marker) and anti-LAMP1 (a major component of lysosomal membrane). In fibroblasts, fine dots of LC3B staining (Fig. 1g) were observed and most of them were not colocalized with LAMP1 (Fig. 1g). Similar to fibroblasts, small dots of LC3B staining were observed in iPSC culture which were not colocalized with LAMP1. However, strong LC3B staining appeared in large vacuoles (Fig. 1c) which colocalized with anti-LAMP1 staining, which could represent different status of LC3B activity. The control double staining was performed with anti-Syntaxin 6, a marker for Golgi membrane, and MitoGreen for mitochondria (Fig. 1d, h). As anticipated, there was no colocalization in either iPSCs (Fig. 1d) or fibroblasts (Fig. 1h). These data therefore demonstrate that large autophagic vacuoles are a characteristic feature of iPSCs which harbor both LC3B-II and LAMP1.
iPSCs exhibit higher abundance of LC3B-II than parental fibroblasts
High basal levels of autophagy components are expressed in iPSCs
Rapamycin induces iPSC autophagy in concentration-dependent and time-dependent manners
To determine whether iPSC maintenance might benefit from upregulated autophagy, we investigated the dosage effect of rapamycin on phosphorylated ULK1, p70S6K, and the autophagy indicator—ratio of LC3B-II/I. Both ULK1 and p70S6K are serine/threonine kinases and targets of mTOR. p70S6K is a major regulator of translation and phosphorylated by mTOR [28, 29, 30], whereas ULK1 is an initiator of autophagy.
We then treated iPSCs with 200 nM of rapamycin for 1, 3, and 6 days, observed significantly clustered LC3B-II staining after 3 days of rapamycin treatment, and showed a time-course-dependent activation of autophagy (Fig. 4e–h). This result was different from that for fibroblasts, in which the total LC3B was increased by 24 hours of rapamycin treatment whereas the LC3B-II remained relatively constant (Additional file 1: Figure S1). These data demonstrate that autophagy can be markedly activated by rapamycin in iPSCs.
Rapamycin attenuates bafilomycin-induced iPSC death
Western blotting showed that bafilomycin enhanced both LC3B-I and LC3B-II bands by blocking basal autophagic flux. Rapamycin induced LC3B expression and caused a shift from LC3B-I to LC3B-II (Fig. 5h, i). Treatment of iPSCs with both rapamycin and bafilomycin A1 increased conversion of LC3B-II from LC3B-I similar to rapamycin treatment alone, thereby attenuating bafilomycin-induced cell death (Fig. 5c, d). These data further strengthen the importance of autophagy in iPSCs, because blockage of fusion of autophagosomes with lysosome rapidly induces iPSC death. Meanwhile, addition of rapamycin significantly improves iPSC survival.
Prolonged treatment with rapamycin induces formation of uniform aggregates
Rapamycin treatment accelerates differentiation of human iPSCs
To examine the differentiation potential of aggregates, we plated them for spontaneous differentiation and comparison with EBs made mechanically. Cells with neuronal morphology appeared after 3 days without neuronal induction (Fig. 8j–l), and many were stained positive for neural stem cell marker NESTIN (Fig. 8m). After 5 days of spontaneous differentiation, we carried out immunocytochemical staining with AFP, ASM, and TUJ1 and obtained significantly higher proportions of cells positive for these makers in cells derived from rapamycin-induced spheres (Fig. 8g–i), compared with cells differentiated from the conventional EBs (Fig. d–f). To illustrate mechanism(s) of rapamycin-induced iPSC differentiation, we investigated NANOG expression after 4 days of treatment by immunoblotting (Fig. 8l). Rapamycin was shown to downregulate NANOG expression in a concentration-dependent manner, and significant reductions were detected at 100 nM (p < 0.05), 200 nM (p < 0.01), or 300 nM of rapamycin treatment (p < 0.01, Fig. 8m). These data suggest that rapamycin-induced spheres are similar to conventional EBs in pluripotency of differentiation, they are non-biased in differentiating into three lineages, but differentiate in an accelerated pace, in association with downregulated NANOG expression during EB formation.
Rapamycin regulates adherens junctions and actin cytoskeleton in human iPSCs
Of the 17 adherens junction molecules, nine (ACTN4, BSG, EPHA2, EZR, FLNB, PDLIM1, PPIA, SHROOM3, RPLP0) were downregulated and eight (ABI2, GSN, ACTR3, ARF6, RALA, RPL7A, RPL19, RPL27) were upregulated (Fig. 9a–c). Of the nine actin cytoskeleton-associated proteins, six (ACTN4, CGN, EZR, FGD4, SERPINA3, TTN) were downregulated and three (CTTNBP2NL, GSN, SEPT11) were upregulated (Fig. 9d, e). Consistent with the morphological changes, these data suggest that alterations of adherens junctions and cytoskeleton are the key pathways in rapamycin-induced iPSC behavior.
Autophagy is a cellular mechanism to maintain minimal cell activity for viability in response to nutrient limitations and cell stress, by degrading and recycling cytoplasmic proteins and subcellular organelles via the fusion of a double-membrane-bound vesicle, autophagosome, and lysosome [17, 33]. Autophagy plays an essential role in cellular reprogramming and the basal level of autophagy increases in aging human skin fibroblasts, which may affect different reprogramming efficiency . There appears no correlation with sex (all male) or age (4–20 years) in the fibroblast lines we have used, but there is correlation with heath status, which requires validation in larger sample sets. In this study we demonstrate abundant presence of large autophagic vacuoles in early fibroblast reprogramming and smaller ones during iPSC maintenance. We show a high basal level of key components of autophagy in 12 iPSC lines derived from 10 independent donors, and prolonged rapamycin treatment resulted spontaneous formation of uniformed sized EBs with accelerated differentiation pace.
In previous studies, lack of autophagy components of Atg3, Atg5, or Atg7 was shown to render MEF cells defective in iPSC colony formation , and lack of two different autophagy genes, atg5 and beclin1, displayed a defect in EB formation during development . The reprogramming was entirely blocked also in Tsc2 –/– somatic cells with hyperactivated mTOR activity which suppressed autophagy . Subtle tuning of the mTOR activity with inhibitors (i.e., 0.3–1 nM rapamycin or 0.1 nM PP242) was found to increase reprogramming efficiency . Mechanistically, the reprogramming factor Sox2 could bind to mTOR promoter and repress mTOR expression and activate autophagy . These data together showed that reduced mTOR activity and elevated autophagy were required during cellular reprogramming, which is consistent with our observation that abundant large autophagic vacuoles are present in early fibroblast reprogramming, which become smaller during the subsequent passaging.
Balanced autophagy and mTOR activity is also essential for the maintenance and differentiation of pluripotent stem cells. Human ES cells were shown previously to have a tight regulation of the mTOR signaling to mediate protein translation for maintaining the pluripotent status . Activation of p70S6K, a mTOR downstream factor, was shown to induce differentiation of human ES cells , whereas inhibition of mTOR autophosphorylation by 20 nM rapamycin was reported to disrupt p70S6K-mediated translation, but not to alter cell viability or expression of the pluripotency markers . In contrast, the mTOR was necessary for growth and proliferation of early mouse embryos and ES cells, and disruption of the mouse mTOR gene prohibited ES cell development [38, 39]. Interestingly, 100 nM rapamycin was previously shown to reduce the size and rate of EB formation in human amniotic fluid stem cells . In contrast, our study demonstrated that a high concentration of rapamycin induced EB formation in iPSCs. Inhibition of the mTOR activity with high concentrations of rapamycin also greatly impaired somatic cell reprogramming , and 100 nM rapamycin was used to primer hepatocyte differentiation of iPSCs prior to Activin A induction . This is consistent with our data that rapamycin downregulates NANOG expression in a concentration-dependent manner and accelerates iPSC differentiation.
To uncover rapamycin pathways in iPSCs, we carried out quantitative mass spectrometry. The STRING Gene Ontology analyses revealed that actin cytoskeleton and adherens junctions were the integrated pathways regulated by rapamycin. For example, ACTN4, BSG, CGN, EPHA2, EZR, FGD4, FLNB, PDLIM1, PPIA, SHROOM3, RPLP0, SERPINA3, and TTN were significantly downregulated, whereas ABI2, CTTNBP2NL, GSN, ACTR3, ARF6, RALA, RPL7A, RPL19, RPL27, and SEPT11 were upregulated.
Actin is critical for cell shape, adhesion, and migration. The dynamics of actin cytoskeleton are modulated by rapamycin targets of SHROOM3, EZR, and GSN. For example, SHROOM3 is required for the apical localization of F-actin/myosin II . EZR links the plasma membrane to actin and is involved in adhesion and migration. Inhibition of EZR expression reduced adhesiveness in colorectal cancer cells . GSN knockdown decreased cell viability and tumor cell invasion, whereas GSN overexpression correlates with proliferative and invasive capacities . BSG promotes cell–cell adhesion, and its downregulation altered the actin/Spectrin network . Reduced expression of SHROOM3, EZR, and BSG in the rapamycin-treated iPSCs is therefore in line with reduced cell adhesion in the literature.
ACTN4, FLNB, and PDLIM1 are actin-binding proteins. ACTN4 is concentrated at sharp extension and at the edge of cell clusters , and FLNB regulates direct communication between the cell membrane and the cytoskeletal network . PDLIM1 functions as an adapter to recruit other LIM-interacting proteins to the cytoskeleton, and suppression of PDLIM1 resulted in cell spreading and the loss of stress fibers and focal adhesions . In addition, ACTR3 is also essential to cell shape and motility, and is an ATP-binding component of the ARP2/3 complex, which regulates actin polymerization. The complex can be activated by ABI, and knockdown of ABI markedly inhibits cell–cell junctions . Rapamycin-induced changes in the expression of ACTN4, ACTR3, FLNB, and PDLIM1 are therefore also likely to affect actin cytoskeleton.
Some of the rapamycin targets are GTPase activity related, such as downregulated EPHA2 and upregulated ARF6 and RALA. GTPases are involved in cell adhesion migration and oncogenic transformation. For example, EphA2 is transmembrane receptor tyrosine kinase activating and prompts cells to round up and detach from their neighbors . RALA is a small GTPase, and constitutively active RALA promotes anchorage-independent growth signaling . ARF6 is a small GTPase to balance with RAB35 GTPase by cells during cell migration and adhesion. Increased ARF6 activity from RAB35 knockdown enhances cadherins accumulation and reduces cell–cell adhesion. The loss of RAB35, however, correlates with enhanced cell migration . Reduced EPHA2 and increased ARF6 and RALA expression may therefore also contribute to rapamycin-induced iPSC detachment. Together these data showed that rapamycin regulates an array of adherens junctions and actin-modifying molecules, which collectively alter iPSC adhesion.
In this study, we demonstrate that autophagy is a prominent feature of reprogramming cells and stable iPSCs. The basal level of autophagy is universally present among human iPSC lines, which is significantly higher than parental fibroblasts. Block of autophagy by bafilomycin induces iPSC death. Rapamycin activates autophagy in concentration-dependent and time-dependent manners and attenuate bafilomycin toxicity in iPSCs. Prolonged rapamycin treatment induces cell detachment and formation of uniformly sized EBs from human iPSCs, with altered expression of adherens junctions and actin-modifying molecules. Rapamycin downregulates NANOG expression, induces EB formation, and accelerates cell differentiation into three germ-layer lineages. These findings are significant in two ways. Firstly, the 3D microenvironment including shape and size of EBs can affect differentiation. The iPSCs are supersensitive to enzyme dissociation and therefore the “hanging drop” technique is difficult to apply, despite being available to generate uniform EBs from ES cells over 20 years ago. Rapamycin may therefore assist generation of uniformly sized EBs with round shape, which may reduce the heterogeneity of the end cell types. Secondly, differentiation of mature and functional cell types from human iPSCs is time consuming, and the accelerated differentiation associated with rapamycin treatment is promising in shortening the differentiation duration. Rapamycin may therefore help overcoming the challenges associated with phenotypic characterization, drug discovery, and cell replacement therapy for neurological disorders.
The authors acknowledge the facilities and technical assistance from the Centre for Microscopy & Imaging at the National University of Ireland Galway (www.imaging.nuigalway.ie), a facility that is funded by National University of Ireland Galway and the Irish Government’s Programme for Research in Third Level Institutions, Cycles 4 and 5, National Development Plan 2007-2013.
This work was supported by Science Foundation Ireland (SFI), Strategic Research Cluster (SRC), grant numbers SFI: 09/SRCB1794 and 09/SRC/B1794s1, SFI Investigator Programme 13/IA/1787, SFI TIDA program 14/TIDA/2258, and NUI Galway Grant RSU002.
Availability of data and materials
AS performed the majority of the experiments. KM and AK made iPSC lines. KM contributed IC/WB data during revisions. MJD and TK contributed additional iPSC lines. JK and VM participated in patient recruitment. KT and PD participated in microscopic characterization. KDC performed independent treatment for proteomics. AvK and AG-M performed proteomics. FB and TO oversaw the project and edited the manuscript. AS and SS designed the experiments, analyzed the data, and wrote the manuscript. All authors read and approved the final manuscript.
AS, BSc, MSc, PhD, postdoctoral researcher, Regenerative Medicine Institute, School of Medicine, NUI Galway, Ireland, and now a lecturer at Chulabhorn International College of Medicine, Thammasat University, Thailand.
KM, BSc, MSc, PhD, postdoctoral researcher, Regenerative Medicine Institute, School of Medicine, NUI Galway, Ireland.
AvK, BSc, MSc, PhD, research fellow, Systems Biology Ireland, University College Dublin, Ireland, and now mass-spectrometry manager at Edinburgh University, UK.
AG-M, BSc, MSc, PhD, laboratory manager, Systems Biology Ireland, Conway Institute, UCD, Ireland.
AK, MSc, Regenerative Medicine Institute, School of Medicine, NUI Galway, Ireland.
KT, BSc, PhD, postdoctoral microscopy facility scientist, School of Medicine, NUI Galway, Ireland.
KDC, MSc, PhD, postdoctor, Regenerative Medicine Institute, School of Medicine, NUI Galway, Ireland.
JK, MB, MD, consultant hematologist and senior lecturer, Galway University Hospital.
VM, MSc, PhD, clinical manager, HRB Clinical Research Facility, NUI Galway, Ireland.
PD, BSc, PhD, Head of Anatomy, Centre for Microscopy and Imaging, School of Medicine, NUI Galway, Ireland.
MJD, MD, PhD, MRC clinical research fellow at MRC center for Regenerative Medicine, The University of Edinburgh, UK.
TK, BSc, MSc, PhD, principal investigator, MRC Center for Regenerative Medicine, The University of Edinburgh, UK.
FB, BSc, MSc, PhD, Professor of Cellular Therapy and Scientific Director of the Regenerative Medicine Institute, School of Medicine, NUI Galway, Ireland.
TO, MB, BCh, BAO, MD, PhD, Director of the Regenerative Medicine Institute, Dean of the College of Medicine and Life Sciences, NUI Galway, Ireland.
SS, BSc, MSc, PhD, Professor of Fundamental Stem Cell Biology, Regenerative Medicine Institute, School of Medicine, NUI Galway, Ireland.
The authors declare that they have no competing interests.
Consent for publication
Informed consent was obtained from volunteers for disclosure of the research data anonymously.
Ethical approval and consent to participate
The iPSC study was carried out in compliance with the ethical approval of the Clinical Research Ethics Committee, Galway University Hospitals, and informed consent was obtained from all participants prior to skin biopsy donation.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.